BACKGROUND: Two opposing models for the action of ghrelin in the behavioral responses to stress were recently proposed. Some studies suggest that an increase in ghrelin contributes to the mechanisms responsible for the development of stress-induced depression and anxiety, while others suggest that it helps minimize what otherwise would be more severe manifestations of depression and anxiety following stress. METHODS: We measured serum ghrelin levels, Profile of Mood States (POMS) scores and State-Trait Anxiety Inventory scores in nonresponders (treatment-resistant patients; 30) and responders (38) with major depressive disorder (MDD), nonresponders (29) and responders (51) with panic disorder and 97 healthy controls. RESULTS: The ghrelin concentration in nonresponders with MDD was higher than that of responders with MDD and normal controls. The ghrelin concentration in nonresponders with panic disorder was higher than that of normal controls. POMS vigor scores in patients with MDD and panic disorder were significantly decreased compared with those in healthy controls. Other POMS scores in patients with MDD and panic disorder were significantly increased compared with those of healthy controls. Trait and state anxiety of the State-Trait Anxiety Inventory in MDD and panic disorder patients were higher than those in healthy controls. CONCLUSIONS: These results indicate that decreased serum ghrelin levels might be associated with antidepressant treatment to confer the maximum therapeutic effect in patients with MDD and panic disorder.
BACKGROUND: Two opposing models for the action of ghrelin in the behavioral responses to stress were recently proposed. Some studies suggest that an increase in ghrelin contributes to the mechanisms responsible for the development of stress-induced depression and anxiety, while others suggest that it helps minimize what otherwise would be more severe manifestations of depression and anxiety following stress. METHODS: We measured serum ghrelin levels, Profile of Mood States (POMS) scores and State-Trait Anxiety Inventory scores in nonresponders (treatment-resistant patients; 30) and responders (38) with major depressive disorder (MDD), nonresponders (29) and responders (51) with panic disorder and 97 healthy controls. RESULTS: The ghrelin concentration in nonresponders with MDD was higher than that of responders with MDD and normal controls. The ghrelin concentration in nonresponders with panic disorder was higher than that of normal controls. POMS vigor scores in patients with MDD and panic disorder were significantly decreased compared with those in healthy controls. Other POMS scores in patients with MDD and panic disorder were significantly increased compared with those of healthy controls. Trait and state anxiety of the State-Trait Anxiety Inventory in MDD and panic disorderpatients were higher than those in healthy controls. CONCLUSIONS: These results indicate that decreased serum ghrelin levels might be associated with antidepressant treatment to confer the maximum therapeutic effect in patients with MDD and panic disorder.
Authors: Christopher A Murgatroyd; Catherine J Peña; Giovanni Podda; Eric J Nestler; Benjamin C Nephew Journal: Neuropeptides Date: 2015-05-28 Impact factor: 3.286
Authors: Alexandra Labarthe; Oriane Fiquet; Rim Hassouna; Philippe Zizzari; Laurence Lanfumey; Nicolas Ramoz; Dominique Grouselle; Jacques Epelbaum; Virginie Tolle Journal: Front Endocrinol (Lausanne) Date: 2014-10-27 Impact factor: 5.555
Authors: Roland Ricken; Sandra Bopp; Peter Schlattmann; Hubertus Himmerich; Tom Bschor; Christoph Richter; Samuel Elstner; Thomas J Stamm; Brigitte Schulz-Ratei; Alexandra Lingesleben; Friedel M Reischies; Philipp Sterzer; Stefan Borgwardt; Michael Bauer; Andreas Heinz; Rainer Hellweg; Undine E Lang; Mazda Adli Journal: Int J Neuropsychopharmacol Date: 2017-09-01 Impact factor: 5.176